Dr. Milica Radisic is a Professor at the University of Toronto, Tier 1 Canada Research Chair in Organ-on-a-Chip Engineering and a Senior Scientist at the Toronto General Research Institute. She is also Director of the NSERC CREATE Training Program in Organ-on-a-Chip Engineering & Entrepreneurship and a co-lead for the Center for Research and Applications in Fluidic Technologies. She is a Fellow of the Royal Society of Canada-Academy of Science, Canadian Academy of Engineering, the American Institute for Medical & Biological Engineering, Tissue Engineering & Regenerative Medicine Society as well as Biomedical Engineering Society. She was a recipient of the MIT Technology Review Top 35 Under 35, Queen Elizabeth II Diamond Jubilee Medal, NSERC E.W.R Steacie Fellowship, YWCA Woman of Distinction Award, Killam Fellowship, Acta Biomaterialia Silver Medal, and Humboldt Research Award to name a few. Her research focuses on organ-on-a-chip engineering and development of new biomaterials that promote healing and attenuate scarring. She developed new methods to mature iPSC derived cardiac tissues using electrical stimulation.

She is an Executive Editor for ACS Biomaterials Science & Engineering, Senior Consulting Editor for the Journal of Molecular and Cellular Cardiology, a reviewing editor for eLife and a member of the editorial board of another 8 journals. She served on the Board of Directors for Ontario Society of Professional Engineers, Canadian Biomaterials Society and McMaster University Alumni Association. She organized Keystone, EMBO and ECI conferences and numerous sessions at TERMIS and BMES meetings.  She served as a Scientific Officer for the Canadian Institutes of Health Research and member of review panels for CIHR, NIH and Israel Ministry of Education. She is the Chair of Investment Committee for Serbia Innovation Fund. She is a co-founder of two companies TARA Biosystems (acquired by Valo Health), that uses human engineered heart tissues in drug development and safety testing, and Quthero that advances regenerative hydrogels. Her work has been presented in over 260 publications, garnering over 25,000 citations with an h-index of 80. Her publications  appeared in Cell, Nature Materials, Nature Methods, Nature Protocols, Nature Communications, PNAS etc.

Prof. Hedtrich obtained her PhD in Pharmaceutical Sciences from the Freie Universität Berlin in 2009. During her postdoc, she moved to the Ludwig-Maximilians-University in Munich and Tufts University in Boston, USA. She held one of the prestigious Johanna-Quandt-Professorships at the Berlin Institute of Health @ Charité in Berlin and currently holds a Tier I Canada Research Chair in Human Disease Models at the School of Biomedical Engineering at the University of British Columbia. Her research centers around inflammatory and genetic diseases of human epithelia with a focus on skin and lungs and bioengineering of complex, human disease models which are leveraged to develop next-generation therapies. She co-/authored over 100 peer-reviewed articles in high-impact journals including the ACS Nano, Small, Nature Reviews Bioengineering, and EMBO Molecular Medicine. 

Hans Clevers has been the Head of Pharma Research and Early Development (pRED) at Roche since 2022. In this role, he is responsible for the strategy, development and management of all aspects of early research and discovery at pRED, from lead identification to target progression to late stage development. In 2023, he oversaw the successful establishment of the Institute of Human Biology, a key long-term investment to bridge the gap between academic and pharmaceutical research in Basel, Switzerland. In addition, he is a member of the expanded Corporate Executive Committee for Roche.
Hans Clevers is world-renowned for his work in the fields of cell biology, molecular signaling and stem cells. His research groups’ discoveries include the detailed characterization of the molecular effectors and integrators of the “Wnt” pathway, which play crucial roles in health and disease, including colon cancer. His group provided important insights into the roles of the LGR5 protein in stem cell regeneration. The Clevers's group pioneered “organoids”, 3-dimensional in vitro structures that behave anatomically and molecularly like the organ from which they are derived. Organoid biology has revolutionized the way we understand and approach human biology and medicine.  (https://www.hubrecht.eu/research-groups/clevers-group/)
Hans Clevers obtained his MD and PhD degrees from the University Utrecht, the Netherlands. He holds a professorship in Molecular Genetics from the University Utrecht. He previously held directorship/President positions at the Hubrecht Institute, the Royal Netherlands Academy of Arts and Sciences and the Princess Maxima Center for pediatric oncology.
He is the recipient of multiple international scientific awards, including the Breakthrough Prize in Life Science.

Hans Clevers is a member of the Royal Netherlands Academy of Arts and Sciences (NL), the National Academy of Sciences (USA), the Royal Society (UK) and the Academie des Sciences (France). He is also Chevalier de la Légion d’Honneur and Knight in the Order of the Netherlands Lion, among many other international accolades.

Professor Christopher Stewart gained PhD in Microbial Ecology at Northumbria University (UK), followed by postdoctoral training at Baylor College of Medicine (Houston, Texas), before starting his lab at Newcastle University (UK) in 2018. He has received numerous awards, including Blavatnik Award for Life Sciences Laureate, Microbiology Society Fleming Prize, NOSTER & Science Microbiome Finalist Prize, the Applied Microbiology International WH Pierce Prize, and the Neonatal Society Rising Star Award. He has also been elected to the Royal Society UK Young Academy and is Editor in Chief of Gut Microbiology.

His lab is focused on microbial-host interaction in the gut of infants born premature (<32 weeks gestation), utilising multi-omic analysis of clinical samples in combination with basic microbiology and an experimental organoid co-culture system. He is also supporting a new UK-wide programme of work aimed at investigating how the gut microbiome predicts response to biological therapy in adult inflammatory bowel disease. He has published over 120 peer-reviewed articles in leading journals, which have wide implications for a better understanding of diet-microbe-host interactions. His work has contributed to the development of novel disease biomarkers and targeted therapeutic interventions to promote human health.

Professor Matthias Lutolf is the founding director of Roche’s Institute of Human Biology (IHB) where he leads the Translational Bioengineering department. The IHB focuses on pioneering research in organoids, human biology, and translational bioengineering, bridging the gap between academic and pharmaceutical research. Lutolf's academic journey began at ETH Zurich, where he studied materials engineering and earned a PhD in biomedical engineering. Following his postdoctoral studies at Stanford University, he established his own laboratory at EPFL in 2007. From 2014 to 2018, he served as the director of EPFL’s Institute of Bioengineering. Lutolf’s own research at IHB is dedicated to developing advanced bioengineering strategies to create next-generation organoids with enhanced reproducibility and physiological relevance, essential for early drug development. His teams' work has been published in renowned journals such as Nature and Science. Additionally, his innovations have led to the commercialization of products, including devices and assays for personalized medicine, and the co-founding of biotech startups in Lausanne.

Seung-Woo Cho is a Professor in the Department of Biotechnology at Yonsei University, Republic of Korea. He earned his B.S., M.S., and Ph.D. degrees in Chemical Engineering from Seoul National University in 1999, 2001, and 2006, respectively. He subsequently completed his postdoctoral training in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT). Professor Cho joined the faculty of Yonsei University in 2010 and was appointed Underwood Distinguished Professor in 2020. Since 2017, he has also served as an associate faculty member at the Institute for Basic Science (IBS), and in 2023, he was named a Yonsei Fellow. His research focuses on engineering stem cells, reprogrammed cells, and organoids using functional biomaterials, nanomaterials, and microdevices for applications in tissue engineering, disease modeling, and drug discovery. He has authored over 220 peer-reviewed publications, which have garnered more than 15,000 citations, and he holds over 160 filed and pending patents. Professor Cho’s contributions to biomedical engineering field have been recognized with numerous awards, including the Asan Award in Medicine (2016), the Scientist of the Month Award (2022), and the Samil Prize (2023). He is also the founder and CEO of CellArtgen, a biotechnology startup established in 2020.

Dr. Margherita Yayoi Turco is a Group Leader at the Friedrich Miescher Institute in Basel, where she leads groundbreaking research on human placental and uterine development. After studying veterinary biotechnology in Bologna and earning her PhD in Milan, she pioneered 3D organoid platforms at Cambridge to model maternal–fetal interactions. Her work addresses critical issues like trophoblast invasion, uterine regeneration, and pregnancy disorders such as pre-eclampsia. Dr. Turco holds high-profile awards (ERC Starting Grant, L’Oréal Women in Science) and continues to publish influential findings using organoid and single-cell technologies.